Israel’s NovellusDx monitors the effect of cancer therapies on a patient’s genetic mutations. NovellusDx reports to the oncologist on the contribution of the driver mutations to the activation of the signaling pathways. NovellusDx has just received $2.5 million funds from the VC Orbimed.
http://www.globes.co.il/en/article-orbimed-invests-25m-in-cancer-profiling-co-novellusdx-1001133996